Tiziana Life Sciences Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed on July 22, 2026, by Tiziana Life Sciences Ltd, a foreign private issuer. The filing reports a significant transaction involving the company's Executive Chairman and Founder, Mr. Gabriele Cerrone, acting through Panetta Partners Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific share purchase transaction rather than periodic financial performance.
Material Changes
- Share Purchase: Mr. Gabriele Cerrone purchased 42,357 common shares at a price of $0.99 per share.
- Updated Holdings: Following the purchase, Mr. Cerrone's total holding stands at 44,814,587 common shares.
- Ownership Percentage: The transaction brings his beneficial interest to 34.93% of the company's issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, operational outlook, or specific risk factors. The document serves solely to disclose the change in beneficial ownership as required by securities regulations.
Investor Verification Checklist
- Verify the current market price of Tiziana Life Sciences Ltd shares relative to the $0.99 purchase price.
- Confirm the total issued share capital to validate the 34.93% ownership calculation.
- Review the attached Exhibit 99.1 (Press Release) for any additional context regarding the strategic intent of the purchase.
- Check for any subsequent filings that may update the beneficial ownership percentage.